PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K

A2

(11) International Publication Number: **WO 98/20834**

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/IB97/01428

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,512 12 November 1996 (12.11.96) US

(71)(72) Applicant and Inventor: TAMARKIN, Dov [IL/IL]; Har Hila 537, 91708 Macabim (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS



(I)

(57) Abstract

A compound effect for the treatment of dermatological disorders comprises a mono– or diester of an α, ω–dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have formula (I), where n is in the range of 6 and 12; m is in the range of 0 and 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR'', CONHR'' and COOR''; R'' is selected from the group consisting of H, alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS

This application claim the benefit of priority under 35 U.S.C. §119(e) to U.S.S.N. 60/030,512 filed November 12, 1996 and entitled "Method for Treatment of Dermatological Disorders", which is hereby incorporated in its entirety by reference.

Field of the Invention

The invention relates to cosmetic or pharmaceutical compositions which contain as an active ingredient, one of novel ester derivatives of α,ω-dicarboxylic acid (6-14 C atoms), covalently linked with a keratolytically active alcohol. The invention further relates to the administration of such compositions in order to treat dermatological disorders.

Background of the Invention

Numerous skin disorders result in the hypertrophy of the stratum corneum, an occurrence also described as hyperkeratinization. The thickened superficial layer of the epidermis results in scale-like plaques on the surface of the skin. These scaly plaques are the manifestation of a group of disorders termed ichthyoses because of their resemblance to fish scales. The plaques may be symptoms of a skin disorder and accordingly prohibit the treatment of these disorders originating in underlying layers of the skin. The hypertrophied skin layer may also harbor infections within itself.

Typical examples of ichthyoses which do not have known etiologies include psoriasis, pityriases, rosacea, and seborrheic dermatitis. These disorders are treated symptomatically with keratolytic agents to remove the plaques and with glucocorticoids to alleviate inflammation. Dermaphytoses are ichthyoses caused by fungal infections. The hyphae and spores are confined to nonviable portions of tissue and thus proliferate in the hyperkeratinized tissues of skin, hair, and nails. Examples of typical dermaphytoses include tinea capitis (cradle cap), tinea pedis (athlete's foot), and tinea unguium. These disorders are treated with anti-fungal agents, and topically with keratolytic agents to remove the cornified and infected layer.

Skin disorders may also be caused by a hormonal imbalance. Such an imbalance may cause increased levels of testosterone, as in the onset of puberty. Testosterone is reduced to dihydrotestosterone (DHT) in target tissues, including the sebaceous glands. In the common dermatological disorder acne, DHT binds to receptors in the pilosebaceous complex and stimulates excessive sebum secretion. The sebum acts as a nutrient for bacteria such as *Propionibacterium acnes,* which infect the sebaceous gland and lead to an inflammatory response and abnormal cornification of the skin. Acne is typically treated with antibacterial and antiseptic agents, and also with keratolytic agents, such as salicylic acid or retinoic acid, to remove the hyperkeratinized tissue.

Skin disorders, such as those described above, create aesthetic disturbances and are often regarded as cosmetically included processes. They may be treated using known medications, however, it is common knowledge that cosmetic products, e.g., soaps, lotions, and shampoos, are also being utilized to combat conditions such as acne, dandruff, seborrhea and androgenic alopecia.

Azelaic acid (AZA) is a naturally occurring nine carbon straight chain molecule with two terminal carboxyl groups. AZA is an anti-keratinizing agent, displaying antiproliferative effects on keratinocytes and modulating the early and terminal phases of epidermal differentiation (Passi, *et al. G. Ital. Dermatol. Venerol.* 1989, 124(10):455-463). AZA is a competitive inhibitor of the reduction of testosterone to dihydrotestosterone, and as such is supposed to reduce the production of sebum in the sebaceous gland. Furthermore, recent investigations have demonstrated that AZA and sebacic acid also have anti-bacterial and anti-fungal properties. Structure-activity relationship studies have revealed that these effects are retained when the α,ω-dicarboxylic acid has an about 6 to about 14 carbon backbone.

Thus, azelaic acid, and other α,ω-dicarboxylic acids, may be used as therapeutic agents in the treatment of skin disorders; however, treatment of the above disorders is hindered by the low bioavailability of such therapeutic agents. Dicarboxylic acids such as azelaic acid are very polar due to the two carboxyl groups. Because of this polarity, skin penetration is very low. In addition, the presence of the acid functional group lowers the pH, which may cause irritation of

the skin. Only high concentrations of the azelaic acid in topical preparations (20%) are effective in treating acne. To demonstrate how weak is the therapeutic effect of AZA lotion, a 20% preparation was effective only after 3-6 months of topical application, twice daily. See, A. Fitton and K. L. Goa, *Drugs* 41: 780-798 (1991). Furthermore, in additional studies topical administration of AZA failed to induce specific changes in sebum composition, sebum excretion rate and the size of sebaceous glands (See for example Mayer-da-Silva et al, 1989, *Acta Derm. Venereol. Suppl.* (Stockholm) **143**: 20-30). Other dermatological agents also comprise a polar functional group, such as a carboxy or hydroxy group, rendering their skin penetration relatively low. Thus there remains a need to increase the efficacy of these drugs in the treatment of skin disorders in which the availability of the drugs through topical application is improved.

α,ω-Dicarboxylic acids, and their mercapto, ester and salt derivatives have been used in the treatment of a variety of skin disorders and/or conditions. Relevant discussions on their uses may be found in the following references.

Hill *et al* in U.S. Pat. No. 4,034,077 teaches the use of a composition comprising sebacic acid for the treatment of skin irritation and the prevention of diaper rash in which the dicarboxylic acid acts as a barrier between the urine and the skin and also neutralizes ammonia. It does not teach the use of sebacic acid in the treatment of any endogenous disorder, including any form of ichthyosis, nor any hormonal imbalance.

Nazzaro-Porro (U.S. Pat. No. 4,292,326) discloses a method of treating hyperpigmentary dermatoses with dicarboxylic acids, such as azelaic acid. These acids, along with their mono- and dimercapto derivatives, are used for their ability to normalize skin color by inhibiting melanogenesis. Nazzaro-Porro (U.S. Pat. No. 4,386,104) teaches the use of the same compounds for the treatment of acne. It also teaches adding a small amount of keratolytic agent to the composition. Nazzaro-Porro (U.S. Pat. No. 5,385,943) also discloses the use of topically applied preparations, comprising an ester of a dicarboxylic acid cleavable by skin enzymes, particularly a glycerol ester, for treatment of presbyderma of the aging skin. It is noted however, that generally any ester may be cleaved by non-specific esterases of the skin, including those esters described in the prior art.

Thornfeldt (U.S. Pat. No. 4,885,282) discloses a treatment of hyperhydrosis, ichthyosis and wrinkling of the skin by means of a mono- or di-carboxylic acids (4-
18C), along with their mercapto derivatives, salts and esters. The use of alkyl, polyol, oligosaccharide and polysaccharide esters, and specifically glycerol, polyethylene glycol, polypropylene glycol and sucrose esters of the respective mono- or di- carboxylic acids is described. UK Pat. Appl. No. GB 2,285,805 teaches the use of esters of dicarboxylic acids with vitamins A, E and D as antitumor agents. Chamness (U.S. Pat. No. 5,547,989) teaches a topical composition comprising dicarboxylic acids (7-13C and specifically AZA), salts and esters thereof for treating corns and calluses. However, no specific ester is claimed or demonstrated by an example.

Sugibayashi *et al* (Chem. Pharm. Bull., 36(4): 1519-1528 (1988)) teaches the use of penetration enhancers for the model compound indomethacin. It discloses the use of salicylates as enhancers because of their ability to soften and dissolve the stratum corneum. They teach the use of salicylates as keratolytic agents to remove the outer layer of cells, which then allows easier penetration of the desired compound.

Luedders, (U.S. Pat. No. 4,299,826) teaches a physical mixture of the antibacterial agent erythromycin, with the penetration enhancer diisopropyl sebacate. Luedders teaches that this additive increases the penetration of erythromycin.

Known references disclose complex esters of straight chain dicarboxylic acids. In U.S. Pat. No. 5,494,924, Cavazza *et al.* teaches the treatment of ichthyoses using complex esters of α,ω-dicarboxylic acids and carnitine. Bilibin *et al.* (USSR Pat. No. 761,452) teaches the synthesis of straight carbon chain α,ω-dicarboxylic acids esterified by reaction with p-hydroxy benzoates, which are used as monomers for the formation of liquid crystalline polymers. In U.S. Pat. No. 3,660,467, Gould teaches phenoxy phenyl esters of α,ω-dicarboxylic acids for use as synthetic lubricants and heat transfer fluids. Portnoy *et al* (Chemical Engineering Data Series, 1958, 3: 287-293) teaches the use of phenyl α,ω-dicarboxylates in the development of nonspreading lubricant oils. Although the

aforementioned an describes compounds comprising esterified α,ω-dicarboxylic acids, there is no discussion of the use of these compounds in treatment of skin disorders.

Thus, there remains a need to provide therapeutic agents for the treatment of skin disorders which demonstrate improved efficacy and reduced irritation over the agents available in the prior art.

Summary of the Invention

It is an object of this invention to provide novel compounds comprising of ester derivatives of α,ω-dicarboxylic acids effective in treating skin disorders and in improving the appearance of the skin.

It is a further object of this invention to provide cosmetic or pharmaceutical compositions comprising such novel ester derivatives for the treatment of skin disorders and improvement of skin appearance.

It is an object of this invention to provide a novel composition with increased penetration across the skin.

It is an object of this invention to provide a novel composition able to treat multiple aspects of a skin disorder.

It is a further an object of the present invention to provide a novel dual-action pro-drug capable of delivering multiple therapeutically active agents to a skin site of a patient.

It is yet a further object of the invention to provide therapeutic treatment effective in mitigating the symptoms of hyperkeratinization, excessive sebum secretion, microbial infection, dermaphytoses, and excessive conversion of testosterone to dihydrotestosterone.

It is still further an object of the invention to provide therapeutic treatment effective in mitigating the symptoms of acne, psoriasis, seborrheic dermatitis, ichthyosis, Rosacea, dandruff, hirsutism, hypertrichosis, and androgenic alopecia.

These and other objects are accomplished by practice of the invention described herein.

In one aspect of the present invention, novel ester derivatives of α,ω-dicarboxylic acids are provided. The compound includes an α,ω-dicarboxylic acid

moiety covalently linked with at least one keratolytically active alcohol moiety. The compound may have the formula,



where *n* is in the range of 6 to 12; *m* is in the range of 0 to 8; R' is H, alkyl, aryl, alkenyl, benzyl, OH, HR", COOR" or CONHR"; R" is H, alkyl, aryl alkenyl or benzyl; and Y is either H, alkyl, aryl, alkenyl, benzyl or X.

The compounds of the invention are useful in the pharmaceutical treatment for mitigation the symptoms of hyperkeratinization, excessive sebum secretion, microbial infection, dermaphytoses, and excessive conversion of testosterone to dihydrotestosterone or in mitigating the symptoms of acne, psoriasis, seborrheic dermatitis, ichthyosis, Rosacea, dandruff, hirsutism, hypertrichosis, and androgenic alopecia.

The compounds of the invention also are useful in cosmetic methods performed by non-medical specialists, i.e., lay persons, for combating conditions such as acne, dandruff, seborrhea and androgenic alopecia.

Detailed Description of the Invention

The present invention provides novel compounds effective in the treatment of skin disorders. Such compounds can either be incorporated into pharmaceutical products, to be prescribed by medical professional or in cosmetic preparations offered directly to customers for self usage.

According to the invention, the compounds include an α,ω-dicarboxylic acid moiety which is covalently linked through an ester bond to a keratolytically active alcohol. The compound may contain one or two alcohols to provide either the respective mono- or diester. As such, the compound comprises two moieties, an α,ω-dicarboxylic acid and a keratolytic agent, each capable of treating the

symptoms of a variety of skin disorders or to improve the appearance of the skin. The compound possesses the additional advantage of providing the two moieties in a form which penetrates rapidly into a dermal site.

An "α,ω-dicarboxylic acid moiety" is used herein to mean a straight carbon chain terminating on both ends with a carboxylic acid functional group. The length of the α,ω-dicarboxylic acid moiety is about 6 to 14 carbons. In a preferred embodiment, the α,ω-dicarboxylic acid moiety comprises between 8 and 10 carbons. The carbon chain backbone may be saturated or unsaturated. In preferred embodiments, the unsaturated backbone may contain 1-3 double bonds. The straight carbon chain also may be substituted, for example, it may be linked to hydrocarbon groups along the carbon atom backbone. Suitable α,ω-dicarboxylic acid moieties include, but are not limited to, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid. In a preferred embodiment, the α,ω-dicarboxylic acid is azelaic acid. Suitable substitutions along the carbon chain backbone include, but are not limited to, alkyl, aryl, alkenyl, and benzyl groups. By way of example only, suitable hydrocabons, e.g., aryl and alkyl substituents, include methyl, ethyl, propyl, phenyl, benzyl and the like.

A "keratolytically active alcohol moiety" is used herein to mean a compound which loosens and removes the stratum corneum of the skin or having an antikeratinizing effect via modulation of keratinocyte differentiation and growth. Suitable keratolytic agent moieties include phenol and substituted phenolic compounds. Suitable substituents include but are not limited to hydroxy groups, -$(CH_2)_m$-COOH and -$(CH_2)_m$-COOR', where m = 0-8 and R' is an aryl, alkyl, alkenyl and benzyl. By way of example only, suitable aryl and alkyl substituents include methyl, ethyl, propyl, phenyl, benzyl and the like. R' and R" are generally selected to impart hydrophobicity to the compound or to improve targeting of the compound to the site of action in order to improve skin penetration. The substituents on the phenyl ring additionally may impart therapeutic properties to the keratolytic phenol. For example, additional hydroxy groups may increase keratolytic performance, and presence of carboxylic acid or alkyl carboxylate substituents may impart anti-inflammatory properties. Other substituents may

increase the hydrophobicity of the moiety. Keratolytic agents include, but are not limited, to hydroxybenzoic acid and their ester, anhydride and amine derivatives, alkylhydroxybenzoate, dihydroxy benzene and their ester, anhydride and amide derivatives, cresols and their ester, anhydride and amide derivatives or alcohol derivatives of Vitamin A.

Many of the suitable keratolytic agents are effective for the treatment of various skin disorders. Salicylic acid (*o*-hydroxybenzoic acid) and its ester derivatives have anti-inflammatory, as well as keratolytic, activity. They are known to dissolve and loosen the intracellular matrix of the hyperkeratinized tissue. As such, they are used in the treatment of dermatological disorders. Dihydroxy benzene and derivatives thereof have been recognized as potent keratolytic agents. Resorcinol (*m*-dihydroxybenzene) and derivatives thereof are used in anti-acne preparations.

Hydroquinone (*p*-dihydroxybenzene), besides its anti-pigmentation properties, is also keratolytic. These compounds also exhibit antiseptic properties. Cresols also possess bactericidal and keratolytic properties. All of these compounds, when used alone, have limited pharmaceutical use because of their poor skin penetration and relatively weak potency. However, when covalently linked to an α,ω-dicarboxylic acid moiety according to the invention, these compounds experience increased skin penetration, and/or increased delivery to the affected site. Thus, the potency of these agents is increased significantly over those of the prior art.

A particularly preferred keratolytic agent is *o*-hydroxybenzoic acid. In other preferred embodiments, it may be desirable to use an alkyl *o*-hydroxybenzoates or an aryl *o*-hydroxybenzoates as the keratolytic alcohols. By way of example only, suitable aryl and alkyl substituents include methyl, ethyl, propyl, phenyl, benzyl and the like. Alkyl and aryl hydroxybenzoates have the added benefit of increased hydrophobicity over the acid counterpart, which increases the skin penetration. Further, aryl and alkyl hydroxybenzoate derivatives of α,ω-dicarboxylic acids form low melting point solids which are liquid at physiological temperatures. This property is useful in enhancing skin penetration.

The particularly preferred compound of the present invention has the

general formula,



where *n* is 6-12; R is OH, COOH and COOR'; and R' may be alkyl, aryl, alkenyl, or benzyl. Y is either H, alkyl, aryl, alkenyl, benzyl or X. Most preferred is a compound where n = 7; R is ortho-COOR'; and R' is an alkyl group. By way of example only, suitable aryl and alkyl substituents include methyl, ethyl, propyl, phenyl, benzyl and the like.

The chemical combination of the α,ω-dicarboxylic acid moieties with the aforementioned alcohols results in compounds having enhanced therapeutic effects for the treatment of skin disorders. Some embodiments have melting points around 30-40°C. These compounds are liquids at physiological temperatures, which increases the ease of skin penetration as compared to compounds which are solids at physiological temperatures.

Skin penetration is directly correlated with hydrophobicity. In the present invention, the polarity of carboxylic acid and hydroxy functional groups is masked by the reaction with one another to form a complex monoester or diester. As a complex ester, the novel derivatives of the present invention are more hydrophobic than the corresponding free α,ω-dicarboxylic acids and free alcohols, and this allows for increased penetration across the skin. With increased penetration, the compound may then exert its therapeutic effects in the underlying layers of the skin. These effects include, but are not limited to, the aforementioned properties of α,ω-dicarboxylic acid moieties, the keratolytic properties and the anti-inflammatory effects of specific alcohols thereof.

The compounds of the present invention may function as dual-action "pro-drugs", i.e., compounds that once delivered to the target site, undergo a chemical or enzymatic cleavage to produce the active form of the two corresponding active agents, namely the α,ω-dicarboxylic acid and the alcohol moiety, in their

pharmacologically active forms. The skin naturally contains non-specific esterases which can effect the necessary cleavage. See, Montagna, W. The Structure and Function of Skin, 1962 2nd edition; and Stevens, C. S. and C-Villez, R.L. *Int. J. Dermatol.* 19:295 (1980). In particular, high concentrations of the nonspecific esterases are located inside the targeted sebaceous glands. See, Holt, R.J. *Br. J. Dermatol.* 85:18 (197). After penetration across the outer layers of the skin, the compounds of the present invention, interact with these esterases. Since the enzymes are not specific, they hydrolyze the ester bond linking the α,ω-dicarboxylic acid moiety and the alcohol moiety. Consequently, two therapeutically effective agents are released in their pharmacologically active forms.

The hydrophobicity of the pro-drug allows the penetration through the naturally occurring outer layers of the skin, as well as through abnormal plaques of hyperkeratinized cells. These plaques are often symptoms of the targeted disorder and barriers to the affected area. The hydrolysis reaction thus occurs in the underlying layers of the skin. The two pharmacologically active agents, capable of treating two or more separate symptoms of a disorder, bypass these barriers to reach the targeted tissue. There, they may then exert their respective therapeutic properties. Thus, it is possible to deliver two therapeutic agents to a target site using the novel compound of the invention.

The increased penetration of the present invention, and thus the improved delivery of the pharmacologically active agents to the targeted tissue, allows for more effective treatment of skin disorders than is known in the prior art. Because the efficiency of delivery is improved, amounts of active ingredients less than is previously disclosed in the prior art will alleviate a skin disorder. In addition, because the acidity of the agent is reduced by esterification, there is reduced inflammation and irritation at the site of application.

Another aspect of the invention is a pharmaceutical or cosmetic composition capable of treating two aspects of a skin disorder. The α,ω-dicarboxylic acid can exert its therapeutic effects on sebum secretion, keratinization of the skin, microbial and fungal infections with concomitant keratolysis of the stratum corneum and/or anti-inflammatory effect, exerted by the phenolic moiety.

In one embodiment of the invention, a composition comprising 10% by

weight (200 mmole/ml) di(ethyl salicylate)azelate was effective in the reduction of comedones in a rabbit ear model. The comedolytic effect of the di(ethyl salicylate)azelate was comparable to the effect of 0.025% Retin A Cream. This comedolytic effect is superior to a 20% (1,060 mmole/ml) azelaic acid preparation disclosed in the prior art. See, Lee, *et al. Kor. J. Dermatol.* 28(5):543-549 (1990).

Additionally, treatment with this composition did not induce any inflammatory response in the treated area, as opposed to the inflammatory effect observed when treated with 0.025% Retin A. Moreover, a comparative skin-irritation test in human volunteers has demonstrated that di(ethyl salicylate)azelate (20%, 400 mmole/ml) did not irritate the skin. In contrast, an equimolar mixture of its components (7.5%, 400 mmole/ml azelaic acid and 11%, 800 mmole/ml salicylic acid) induced an inflammatory reaction, including moderate erythema, slight edema, and local pruritus. An in-vivo dermal irritation test in rabbits also demonstrated no signs of irritation following 24 hour application of di(ethyl salicylate)azelate (10% and 20%). These findings emphasize a distinct advantage of di(ethyl salicylate)azelate over its parent components.

The sebolytic effect of di(ethyl salicylate)azelate was revealed in a human test. Following fourteen days of topical treatment, the skin oiliness of the forehead of a human volunteer, tested using a photometric instrument was reduced from 223 units (resembling "oily skin") to 205 units (normal skin value). This finding demonstrates the superiority of the compounds of the invention over azelaic acid, which according to published literature can not alter skin oiliness.

The direct effect of the compounds of the invention on the proliferation of human keratinocytes was assessed in vitro using a keratinocyte cell line. It was found that compounds of the invention are strong inhibitors of keratinocyte proliferation. Di(ethyl salicylate)azelate inhibited cell proliferation at a concentration of 0.3 mM and di-retinyl azelate was inhibitory at a concentration of 15 μM. The cytotoxic respective concentrations of the same agents were 3 mM and 100 μM, allowing a substantial therapeutic safety margin of 6.6-10. In contrast, the inhibitory concentration of azelaic acid was as high as 1 mM and its cytotoxic concentration was only 2.6 times higher. Hence, utilizing the compounds of the invention in treatment of skin disorders that involve hyperkeratinization is

advantageous over using free azelaic acid.

A preferred embodiment is a pharmaceutical or cosmetic composition comprising a therapeutically effective amount of the novel compound described herein and a pharmaceutically or cosmetically acceptable carrier. With respect to a "pharmaceutically acceptable carrier", as used herein, it is meant any liquid, gel, emulsion, cream, ointment, fluid ointment base, solvent, diluent and the like which is suitable for use in contact with living mammalian tissue, which is desirably capable of dissolving the therapeutically active agents of the invention, and which will not interact with the other components of the composition in a deleterious manner. Alcohols are particularly preferred carriers. Additives to such compositions may include, but are not limited to, preservatives, moisturizers, petroleum, thickening agents, alpha-hydroxy carboxylic acids, mineral oil, pigments and other components described in the CTFA handbook of cosmetic ingredients. It would be apparent to those of ordinary skill in the art of dermatology that the resulting compositions can be in many forms including, but not limited to, solutions, lotions, creams, pastes, emulsions, gels, soap bars, sprays or aerosols. Such compositions may be applied manually, or using various application devices.

One aspect of the invention is a pharmaceutical or cosmetic composition for the treatment of hyperkeratinization. Another aspect of the invention is an effective composition and method of treating dermatological disorders resulting from a hormonal imbalance in target tissues. It has been suggested that α,ω-dicarboxylic acids inhibit the reduction of testosterone to dihydrotestosterone (DHT). By inhibiting this conversion, α,ω-dicarboxylic acids act as therapeutic agents in the treatment of disorders cause by an increase in the amount of dihydrotestosterone. DHT is the androgen responsible for the development of secondary sex characteristics. Increased levels of DHT may cause excessive hair growth, a disorder known as hypertrichosis. Both males and females may be afflicted by hypertrichosis in which there is increased hair growth on any part of the body. Another disorder which strikes females and is caused by increased levels of DHT is hirsutism. In this disorder, the increased levels of androgens cause the subject to develop male hair growth patterns. Since the aforementioned disorders are caused by an increased level of DHT at the hair follicle, they are frequently accompanied

by an increased occurrence of acne. The increased penetration of the composition of the invention provides a method of delivering α,ω-dicarboxylic acid moieties to the underlying layers of the skin. Thus, the composition of the invention is expected to be effective in the treatment of secondary effects of hormonal imbalance.

Androgenic alopecia, also termed male pattern baldness, is a predominantly hereditary disease which is the most common cause of hair loss in men. The hair follicles have an increased sensitivity to DHT and to its subsequent breakdown products, which are thought to inhibit hair growth in the scalp. Thus, an increase in the amount of DHT at the hair follicle would increase this inhibition and lead to hair loss. Androgenic alopecia may also afflict women. Increased levels of circulating androgens in women may be caused by endocrine disorders, such as ovarian or adrenal dysfunction. In these women the excessive amounts of the androgen in the target tissue, specifically the hair follicles, inhibits hair growth and ultimately results in hair loss. The composition of the invention is expected to effectively reduce the amount of DHT at the hair follicles. This reduction will decrease the inhibition and promote hair growth.

Another aspect of the invention is a method of treating a particular skin disorder by applying a composition comprising an effective amount of the compound mixed with a pharmaceutically or cosmetically acceptable carrier to the affected area. The composition contains a therapeutically effective amount of the novel mono- or diester of the invention. The actual effective amount may vary dependent upon the particular skin disorder treated; however, it is generally contemplated that composition having 0.1%-30% (weight per volume) may be used in accordance with the invention. The composition may be applied topically to the affected area. By "topical" application as that term is used herein it is meant directly spreading or laying on the epidermal tissue. The application may be made by rubbing, by using medicated pads or by any other convenient means. Due to the very low toxicity of the compound of the invention, oral, nasal or parenteral administration of the agent is also applicable.

The novel compound of the invention may be prepared according to methods known in the art. Ester synthesis from carboxylic acids and their

derivatives is well known to those with ordinary skill in the art. A carboxylic acid and an alcohol may be combined in the presence of an acid catalyst to obtain the desired ester and water. The acyl halide derivative, or other suitable derivative (e.g. tosyl, mesityl, etc.) of the carboxylic acid will also effectively produce the desired ester. For a review of ester synthesis, the reader is directed to Vollhardt, Organic Chemistry, Chapter 17.

The following examples are illustrative of the present invention, without constituting any limitations thereon.

Example 1. Synthesis of *Nonanedioic acid, di-[(2'-ethoxycarbonyl)phenyl] ester* (also termed herein "di(ethyl salicylate)azelate"). 80 mmole ethyl salicylate is dissolved in 50 ml pyridine in a three neck flask equipped with a nitrogen inlet and outlet. The solution is cooled to 0 °C. Azelaoyl chloride (40 mmole) is added dropwise over 1 hour with magnetic stirring. The reaction mixture is stirred for 2 hours at room temperature and then poured into 200 ml 5% HCl. The mixture is extracted 3 times with methylene chloride and the organic phase is worked up with sodium bicarbonate and water, and evaporated to give a viscous off-white product. The product is purified on a silica gel column using 3:5 ethyl acetate:hexane as an eluent. It is then evaporated and mixed overnight with 50 ml hexane to give 11.6 grams (24 mmole; 60% yield) white powder (mp = 34-35 C; MW= 485). The compound was characterized by NMR and IR. NMR:1.25-2.04, m, 10H; 2.63, t, 4H; 4.32, dd, 4H; 7.08, d, 2H; 7.30, t, 2H; 7.52, t, 2H; 7.99, d, 2H; and IR: 1769, 1757, 1713, 1606, 1365, 1255, 1198, 1140, 1088, 770, 715. Elemental analysis: C = 67.25 (calc. 66.94); H = 6.68 (calc. 6.61).

Example 2. Synthesis of *o,o-di-(7-methoxycarbonyl-1-octanoyl-1,4-dihydroxybenzene)*. 20 grams (100 mmole) azelaic acid monoethyl ester is added dropwise over a period of 5 hours into 24 grams (14.7 mmole) $SOCl_2$ over a 40-50 C water bath. The $SOCl_2$ was distilled out, and the resulting acyl chloride was slowly dropped into 12 grams (110 mmole) hydroquinone at room temperature with magnetic stirring. The reaction mixture was further stirred at room temperature for 16 hours, then poured into 5% HCl. It was extracted with methylene chloride, washed with water, dried and evaporated. Crystallization from toluene gave 17 grams (58 mmole; yield=58%) pale-brown solid (mp = 53-56 °C). The compound

was characterized by NMR. NMR: 1.31-1.77, m, 20H; 2.3, t, 4H; 2.54, t, 4H; 3.67, s, 6H; 7.07, s, 4H.

Example 3. Synthesis of *o-(7-methoxycarbonyl-1-octanoyl-1,4-dihydroxybenzene)*. 20 grams (100 mmole) azelaic acid monomethyl ester is added dropwise over the course of 5 hours into 24 grams (14.7 mmole) $SOCl_2$ over a 40-50 °C water bath. $SOCl_2$ was distilled out, and the resulting acyl chloride was slowly dropped into 5.5 grams (50 mmole) hydroquinone at room temperature with magnetic stirring. The reaction mixture was further stirred at room temperature for 16 hours, then poured into 5% HCl. It was extracted with methylene chloride, washed with water, dried, evaporated and mixed overnight with 50 ml hexane, to give 9.5 grams (20 mmole; yield=40%) white powder. The compound was characterized by NMR and IR. NMR: 1.31-1.77, m, 10H; 2.32, t, 2H; 2.53, t, 2H; 3.67, s, 3H; 5.60, broad s, 1H; 6.82, dd, 4H; and IR: 3458, 2943, 1740, 1510, 1444, 1267, 1223, 1149.

Example 4. Synthesis of di-retinyl azelate. Vitamin A (retinol, 0.86 g, 3 mmole) was dissolved in 2 ml pyridine and 7.5 ml methylene chloride in a 25 ml flask equipped with a calcium chloride vent. The solution was cooled over an ice bath. Azelaoyl chloride (0.3 ml, 0.345 g, 1.5 mmole) was added with magnetic stirring. The reaction mixture was stirred for 2 hours at room temperature and then poured into 10 ml 5% HCl/ice. The mixture was extracted 3 times with methylene chloride and the organic phase is washed with sodium bicarbonate and water, dried with magnesium sulfate and evaporated. The product was purified on a silica gel column, to yield 0.5 gr. (0.7 mmole, yield = 46%). The compound was characterized by NMR: 1.0, s, 12H; 1.3-1.6, m, 18H; 1.70, s, 6H; 1.88, s, 6H; 1.95, s, 6H; 2.0, t, 4H; 2.30, t, 4H; 4.72, d, 4H; 5.6, t, 2H, 6.0-6.2, m, 6H; 6.27, d, 2H; 6.63, t, 2H.

Example 5. Preparation of an antiacne/antiseborrheic lotion. 10 grams of di(ethyl salicylate)azelate is dissolved in 10 ml ethanol and 90 ml PEG400 to give a clear, colorless solution with viscosity <100cps.

Example 6. Efficacy of di(ethyl salicylate)azelate (10%) in the rabbit ear acne model. Three mature male albino rabbits were treated as follows. The external ear canals on both ears were treated once daily for five weekdays for three

weeks with 1% crude coal tar in Hydrophilic Ointment USP. Then one ear was treated with antiacne lotion of Example 4 once daily for five weekdays for three weeks while the opposite ear served as an untreated control. Excision biopsies were taken from both sides at the end of three weeks of treatment. These were fixed in formalin, semi-serial sectioned and stained with H and E. The untreated ears showed compact hyperkeratosis of the sebaceous ducts. These were judged to be moderate examples of comedones with distortion of the follicular infundibulum by dense horn. All three treated ears showed a marked reduction of the comedones. A few follicles showed a small amount of residual horn but this was loose and not compact. The comedolytic effect of di(ethyl salicylate)azelate was comparable to the effect of 0.025% Retin A Cream. There was no inflammatory reaction resulting from the treatment.

Example 7. Human skin irritation test. The following lotions (0.1 ml) were applied to the skin of a human subject for 48 hours, using standard skin irritation test chambers (0.64 sq. cm.):

(1) 20% di(ethyl salicylate)azelate (400 mmole/ml), dissolved in PEG-400/ethanol 1: 1;

(2) mixture of 7.5% azelaic acid (400 mmole/ml) and 11% salicylic acid (800 mmole/ml), dissolved in PEG-400/ethanol 1:1; and

(3) PEG-400/ethanol 1:1 (placebo).

Upon removal of the chambers and 1, 24 and 48 hours later, there was no sign of any skin reaction resulting from the application of either the placebo or di(ethyl salicylate)azelate. The equimolar mixture of the prodrug-components (2) induced an inflammatory response including moderate erythema, slight edema, and local pruritus.

Example 8. Acute dermal toxicity/irritation test. The purpose of this study was to evaluate the acute potential dermal irritation effect on skin following the topical application of di(ethyl salicylate) azelate, in rabbits. This test is a modified version of the original Draise method, as described in OECD guidelines. 0.5 ml of either di(ethyl salicylate)azelate (10% or 20%, dissolved in PEG-400/ethanol 1:1) or the vehicle alone were applied to the skin of three rabbits for 24 hours. Rabbits were examined for signs of skin irritation 1, 24 and 72 hours after the removal of

the test solutions. Throughout the study, no signs of skin irritation were observed. Based on the current protocol it was concluded that di(ethyl salicylate) azelate is a non-irritant agent.

Example 9. Acute subcutaneous toxicity limit test. Five male and five female ICR mice were administered subcutaneously 2000 mg/kg of di(ethyl salicylate) azelate, then followed up for fourteen days. No toxic effects were observed throughout the treatment and observation period, indicating that di(ethyl salicylate) azelate may be regarded as non-toxic.

Example 10. Sebolytic effect of di(ethyl salicylate)azelate. The antiacne/antiseborrheic lotion of Example 5 was topically applied twice daily to the forehead of a woman who had oily skin prior to treatment. Skin oiliness was tested using "Skin Tester, Model STC20" (IMS Ltd., Haifa, Israel) prior to treatment and 14 days thereafter. Prior to treatment, the sebum value was 223 units, typical of oily skin. The sebum value after two weeks of treatment was 205 units, corresponding to normal skin.

Example 11. Antipsoriatic gel. 20g di(ethyl salicylate)azelate is dissolved in 50 ml ethanol and 50 ml water. The solution is warmed to 60C with stirring and 1g PEG-4000 is added. The mixture is cooled to room temperature and a gentle magnetic stirring is applied for 2 hours.

Example 12. Modulation of keratinocyte proliferation. The effect of di(ethyl salycilate)azelate and di-retinyl azelate on cell proliferation and cell viability was tested in vitro using human keratinocyte culture system.

Cell proliferation assay. 50,000 human keratinocytes from secondary culture were seeded into 24 well plates, in 1 ml DMEM-F12 medium (Green H. (1978) Cell 15:801-805) with growth factors and 10% Fetal Calf Serum. The cells were incubated at 37 °C in 5% CO_2 until 30-40% confluency was reached and then the various test materials, dissolved in ethanol, were added in volumes of 0.1-20 µl, to final volume of 0.5 ml. The same volumes of ethanol were added to control cultures, for comparative values of ethanol cytotoxicity. No apparent cytotoxicity was found up to 40 µl/ ml ethanol. The medium was replaced with fresh medium prior to addition of the test materials. The cultures were further incubated for 3 days at 37°C and 5% CO_2 and then washed with phosphate buffered saline (PBS).

Cell numbers were determined using two methods: 1) trypsinization, followed by cell counting; and 2) fixation of the culture with p-formaldehyde 2% in PBS and methylene blue staining, followed by extraction of color and optical density measurement at 650 nm. Both methods were found in good correlation, so that 1 OD unit corresponded to 1,000,000 cells. IC50, i.e., the concentration that caused 50% inhibition of cell proliferation for each of the test materials is presented in Table 1.

Cytotoxicity test. Keratinocyte cells, as above, were allowed to proliferate in medium, without the test materials, up to 100% confluency, with one exchange of medium during growth. Confluent cultures were incubated with increasing concentrations of the test materials in ethanol for three days at 37°C and 5% CO_2. At the end of the incubation period the cultures were washed with PBS and measured for remaining attached cells using the above described methods. LC50, i.e., the concentration that caused 50% cytotoxicity is also presented in Table 1.

Table 1 demonstrates that di-retinyl azelate and di(ethyl salicylate) azelate are significantly more potent than azelaic acid and salicylic acid in inhibiting cell proliferation. Moreover, their cytotoxic concentrations were 6.6-10 fold higher than their inhibitory concentrations, rendering them safer than free azelaic acid.

Table 1 : IC50 (inhibitory concentration) and LC50 (cytotoxic concentration) of compounds of the invention, azelaic acid and salicylic acid

Test Material	IC50	LC50	Safety factor (CD50/ID50)
Di-retinyl azelate	15 µM	100 µM	6.6
Di(ethyl salicylate) azelate	0.3 mM	3 mM	10
Azelaic acid	1.5 mM	4 mM	2.6
Salicylic acid	1.5 mM	ND	NA

What is claimed is:

1. A compound, comprising:

an α,ω-dicarboxylic acid covalently linked through an ester bond with at least one keratolytically active alcohol moiety, having the formula,



where *n* is in the range of 6 and 12; *m* is in the range of 0 and 8; R' is selected from the group consisting of H alkyl, aryl, alkenyl, benzyl, OH, NHR", CONHR" and COOR"; R" is selected from the group consisting of H, alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

2. A compound, comprising:

a mono- or diester of an α,ω-dicarboxylic acid, wherein the ester moiety of the dicarboxylic acid comprises a keratolytically active alcohol.

3. The compound of claim 1 or 2, wherein the α,ω-dicarboxylic acid moiety comprises about 6 to 14 carbon atoms.

4. The compound of claim 1 or 2 wherein the α,ω-dicarboxylic acid moiety comprises 8 to 10 carbon atoms.

5. The compound of claim 1 or 2 wherein the α,ω-dicarboxylic acid carbon chain backbone is unsaturated.

6. The compound of claim 5, wherein the backbone comprises about one to three double bonds.

7. The compound of claim 1 or 2 wherein the carbon chain of the α,ω-dicarboxylic acid moiety is linked to a hydrocarbon substituent.

8. The compound of claim 1 or 2 wherein the carbon chain of the α,ω-dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups

9. The compound of claim 1 or 2 wherein said α,ω-dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

10. The compound of claim 1 or 2, wherein said α,ω-dicarboxylic acid comprises azelaic acid.

11. The compound of claim 1 or 2, wherein said keratolytically active alcohol comprises salicylic acid or a derivative thereof.

11a. The pharmaceutical or cosmetic composition of claim 13 or 14, wherein said keratolytic alcohol is selected from a group consisting of ortho-, meta- and para-hydroxybenzoic acid, ortho-, meta- and para-hydroxyalkylbenzoate, ortho-, meta-, and para-dihydroxybenzene, ortho-, meta-, and para-hydroxytoluene and derivatives thereof.

12. The compound of claim 9, wherein said keratolytically active alcohol to comprises salicylic acid or a derivative thereof.

13. A pharmaceutical or cosmetic composition, comprising:

a therapeutically effective amount of a compound comprising a mono- or diester of an α,ω-dicarboxylic acid, wherein the ester comprises a keratolytically active alcohol; and

a pharmaceutically acceptable carrier.

14. The pharmaceutical or cosmetic composition of claim 13, wherein said α,ω-dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

15. The pharmaceutical or cosmetic composition of claim 13 or 14, wherein the α,ω-dicarboxylic acid comprises azelaic acid.

16. The pharmaceutical or cosmetic composition of claim 13 or 14, wherein said keratolytic alcohol is selected from a group consisting of ortho-, meta- and para-hydroxybenzoic acid, ortho-, meta- and para-hydroxyalkylbenzoate, ortho-, meta-, and para-dihydroxybenzene, ortho-, meta-, and para-hydroxytoluene and derivatives thereof.

17. The pharmaceutical or cosmetic composition of claim 13 or 14, wherein said keratolytically active alcohol comprises an alkyl derivative of ortho-, meta- and para-hydroxyalkylbenzoate.

18. The composition of claim 13 or 14, wherein said compound comprises two keratolytically active alcohol moieties.

19. The pharmaceutical or cosmetic composition of claim 13 or 14, wherein said therapeutically effective amount of said compound comprises an amount effective to treat dermatological disorders selected from the group consisting of hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

20. A method of treating dermatological disorders, comprising:

administering topically, nasally, orally or parenterally a therapeutically effective amount of a compound comprising a therapeutically effective amount of a compound comprising a mono- or diester of an α,ω-dicarboxylic acid, wherein at

least one alcohol moiety of the said ester comprises a keratolytically active alcohol to a subject having said dermatological disorder.

21. A method of treating dermatological disorders, comprising:

applying topically a therapeutically effective amount of a compound comprising a therapeutically effective amount of a mono- or diester of an α,ω-dicarboxylic acid, wherein at least one alcohol moiety of the said ester comprises a keratolytically active alcohol to the affected area.

22. The method of claim 20 or 21, wherein said dermatological disorder is linked to hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

23. The method of claim 20 or 21 wherein said dermatological disorder is selected from a group consisting of acne, seborrheic dermatitis, dandruff, psoriasis, ichthyosis, Rosacea, hirsutism, hypertrichosis, and androgenic alopecia.

24. A method of increasing penetration of an α,ω-dicarboxylic acid across dermal layer, comprising:

applying a mono or diester derivative of the α,ω-dicarboxylic acid to the dermal layer, said ester moiety comprises a keratolytically active alcohol.

25. Compounds of claims 1 to 12, which are functional to release a plurality of dermatologically-active compounds when delivered to a target site of the skin.

26. Compositions of claims 13 to 19, which are functional to release a plurality of dermatologically-active compounds when delivered to a target site of the skin.

27. The compounds of any of claims 1 to 12, for use in treating

dermatological disorders.

28. Use of a compound comprising a mono- or diester of an α,ω-dicarboxylic acid, wherein the ester moiety of the dicarboxylic acid comprises a keratolytically active alcohol, for the manufacture of a pharmaceutical composition in topically, orally or parenterally administrable form, for treating dermatological disorders.

29. The use of claim 28, wherein the dermatological disorder is linked to hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

30. The use of claim 28, wherein the dermatological disorder is selected from acne, seborrhoeic dermatitis, dandruff, psoriasis, ichthyosis, Rosacea, hirsutism, hypertrichosis and androgenic alopecia.

31. Use of a mono- or diester derivative of an α,ω-dicarboxylic acid wherein the ester moiety comprises a keratolytically active alcohol, for the manufacture of a composition for increasing penetration of the α,ω-dicarboxylic acid across a dermal layer.

32. The use according to any of claims 28 to 31, wherein the compound or derivative is a compound according to any of claims 1 to 12.

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07C 53/00, 101/00, A61K 31/215, 31/235, 31/22, 31/225, 31/23

A3

(11) International Publication Number: WO 98/20834

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/IB97/01428

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,512 12 November 1996 (12.11.96) US

(71)(72) Applicant and Inventor: TAMARKIN, Dov [IL/IL]; Har Hila 537, 91708 Macabim (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
26 November 1998 (26.11.98)

(54) Title: METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS



(I)

(57) Abstract

A compound effect for the treatment of dermatological disorders comprises a mono– or diester of an α, ω–dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have formula (I), where n is in the range of 6 and 12; m is in the range of 0 and 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR'', CONHR'' and COOR''. R'' is selected from the group consisting of H, alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB97/01428

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07C 53/00, 101/00; A61K 31/215,31/235, 31/22, 31/225, 31/23

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/529, 532, 533, 546, 547, 548, 552, 554; 554/103, 108, 109, 110, 227, 229

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

cas online, aps, medline

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Chem. Abstr., Vol. 119, No. 26, 27 December 1993 (Columbus OH, USA), pages 531-532, columns 2 & 1, the abstract No. 278796w, DANNHARDT, G. et al 'Topical pharmaceutical preparation containing glycerol nitrate as penetration enhancer' DE 4,213,419.	1-5, 7, 9-10, 13-15
X	US 5,387,672 A (BUCCI et al.) 07 February 1995, entire document.	1-24, 28-32

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

*	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search 14 SEPTEMBER 1998	Date of mailing of the international search report 13 OCTOBER 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer DEBORAH CARR Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB97/01428

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 25-27
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB97/01428

A. CLASSIFICATION OF SUBJECT MATTER:
US CL :

514/529, 532, 533, 546, 547, 548, 552, 554; 554/103, 108, 109, 110, 227, 229

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :
C07C 53/00, 101/00, A61K 31/215, 31/235, 31/22, 31/225, 31/23

A3

(11) International Publication Number: WO 98/20834

(43) International Publication Date: 22 May 1998 (22.05.98)

(21) International Application Number: PCT/IB97/01428

(22) International Filing Date: 12 November 1997 (12.11.97)

(30) Priority Data:
60/030,512 12 November 1996 (12.11.96) US

(71)(72) Applicant and Inventor: TAMARKIN, Dov [IL/IL]; Har Hila 537, 91708 Macabim (IL).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
With amended claims.

(88) Date of publication of the international search report:
26 November 1998 (26.11.98)

Date of publication of the amended claims:
21 January 1999 (21.01.99)

(54) Title: METHOD FOR TREATMENT OF DERMATOLOGICAL DISORDERS



(57) Abstract

A compound effect for the treatment of dermatological disorders comprises a mono- or diester of an α, ω–dicarboxylic acid, wherein the alcohol moiety of the said ester comprises a keratolytically active alcohol. The compound may have formula (I), where n is in the range of 6 and 12; m is in the range of 0 and 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR'', CONHR'' and COOR''; R'' is selected from the group consisting of H, alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

AMENDED CLAIMS
[received by the International Bureau on 7 December 1998 (07.12.98);
original claims 1-32 replaced by new claims 1-49 (8 pages)]

1. A compound, comprising:

an α,ω-dicarboxylic acid covalently linked through an ester bond with at least one keratolytically active alcohol moiety, having the formula,



where *n* is in the range of 6 and 4 to 12; *m* is in the range of 0 to 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OR", NHR", CONHR" and COOR"; R" is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

2. The compound of claim 1, characterized in that the compound is a liquid at body temperature.

3. The compound of claim 1, wherein the α,ω-dicarboxylic acid moiety comprises about 6 to 14 carbon atoms.

4. The compound of claim 1, wherein the α,ω-dicarboxylic acid moiety comprises 8 to 10 carbon atoms.

5. The compound of claim 1, wherein the α,ω-dicarboxylic acid carbon chain backbone is unsaturated.

6. The compound of claim 5, wherein the backbone comprises about one to three double bonds.

7. The compound of claim 1, wherein the carbon chain of the α,ω-dicarboxylic acid moiety is linked to a hydrocarbon substituent.

8. The compound of claim 1, wherein the carbon chain of the α,ω-dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups

9. The compound of claim 1, wherein said α,ω-dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

10. The compound of claim 1, wherein said α,ω-dicarboxylic acid comprises azelaic acid.

11. The compound of claim 1, wherein said keratolytically active alcohol moiety comprises an ester, anhydride or amide derivative of salicylic acid or a derivative thereof.

12. A pharmaceutical or cosmetic composition, comprising:

a therapeutically effective amount of a compound comprising a mono- or diester of an α,ω-dicarboxylic acid, wherein the ester comprises a keratolytically active alcohol moiety, having the formula,



where *n* is in the range of 4 to 12; *m* is in the range of 0 to 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR", CONHR" and COOR"; R" is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X; and

a pharmaceutically acceptable carrier.

13. The pharmaceutical or cosmetic composition of claim 12, wherein said α,ω-dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

14. The pharmaceutical or cosmetic composition of claim 12, wherein the α,ω-dicarboxylic acid comprises azelaic acid.

15. The composition of claim 12, wherein the compound is a liquid at body temperature.

16. The composition of claim 12, wherein the ",T-dicarboxylic acid carbon chain backbone is unsaturated.

17. The composition of claim 16, wherein the backbone comprises about one to three double bonds.

18. The composition of claim 12, wherein the backbone of the ",T-dicarboxylic acid moiety is linked to a hydrocarbon substituent.

19. The composition of claim 12, wherein the backbone of the ",T-dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups

20. The pharmaceutical or cosmetic composition of claim 12, wherein said keratolytic alcohol is selected from a group consisting of ortho-, meta- and para-hydroxybenzoic acid, ortho-, meta- and para-hydroxyalkylbenzoate, ortho-, meta-, and para-dihydroxybenzene, ortho-, meta-, and para-hydroxytoluene and derivatives thereof.

21. The pharmaceutical or cosmetic composition of claim 12, wherein said keratolytically active alcohol comprises an alkyl derivative of ortho-, meta- and para-hydroxyalkylbenzoate.

22. A pharmaceutical or cosmetic composition, comprising:

a therapeutically effective amount of a compound comprising a mono- or diester of an α,ω-dicarboxylic acid, wherein the ester comprises a retinol moiety or derivatives thereof; and

a pharmaceutically acceptable carrier.

23. The composition of claim 12 or 22, wherein said therapeutically effective amount of said compound comprises an amount effective to treat skin disorders.

24. The pharmaceutical or cosmetic composition of claim 12 or 22, wherein said therapeutically effective amount of said compound comprises an amount effective to treat dermatological disorders selected from the group consisting of hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

25. A method of treating dermatological disorders, comprising:

administering topically, nasally, orally or parenterally to a subject having said dermatological disorder a therapeutically effective amount of a compound comprising a therapeutically effective amount of a compound comprising a mono-or diester of an α,ω-dicarboxylic acid, wherein at least one alcohol moiety of the said ester comprises a keratolytically active alcohol moiety, the compound having the formula to a subject having said dermatological disorder



where *n* is in the range of 4 to 12; *m* is in the range of 0 to 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR", CONHR" and COOR"; R"

is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

26. The method of claim 25, wherein said compound is applied topically to the affected area.

27. The method of claim 25 or 26, wherein the compound is a liquid at body temperature.

28. The method of claim 25 or 26, wherein said dermatological disorder is linked to hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

29. The method of claim 25 or 26, wherein said dermatological disorder is selected from a group consisting of acne, seborrheic dermatitis, dandruff, psoriasis, ichthyosis, Rosacea, hirsutism, hypertrichosis, and androgenic alopecia.

30. The method of claim 25 or 26, wherein said dermatological disorder comprises dermatoses.

31. The method of claim 25 or 26, wherein said α,ω-dicarboxylic acid is selected from the group consisting of adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,11-undecanedioic acid, 1,12-dodecanedioic acid, 1,13-tridecanedioic acid and 1,14-tetradecanedioic acid.

32. The method of claim 25 or 26, wherein the α,ω-dicarboxylic acid comprises azelaic acid.

33. The method of claim 25 or 26, wherein the α,ω-dicarboxylic acid carbon chain backbone is unsaturated.

34. The method of claim 25 or 26, wherein the backbone comprises about one to three double bonds.

35. The method of claim 25 or 26, wherein the carbon backbone of the α,ω-dicarboxylic acid moiety is substituted by a hydrocarbon substituent.

36. The method of claim 25 or 26, wherein the carbon backbone of the α,ω-dicarboxylic acid moiety is substituted by alkyl, aryl, alkenyl or benzyl groups.

37. The method of claim 25 or 26, wherein said keratolytic alcohol moiety is selected from a group consisting of ortho-, meta-and para-hydroxyalkylbenzoates, ortho-, meta-, and para-dihydroxybenzene, ortho-, meta-, and para-hydroxytoluene and derivatives thereof.

38. The method of claim 25 or 26, wherein said keratolytically active alcohol moiety comprises an alkyl derivative of ortho-, meta-and para-hydroxyalkylbenzoate.

39. A method of treating dermatological disorders, comprising:

administering topically, nasally, orally or parenterally to a subject having said dermatological disorder a therapeutically effective amount of a compound comprising a mono-or diester of an α,ω-dicarboxylic acid, wherein at least one of the said ester comprises a keratolytically active alcohol moiety, comprises a retinol moiety or derivatives thereof.

40. A method of increasing penetration of an α,ω-dicarboxylic acid across dermal layer, comprising:

applying a mono or diester derivative of the α,ω-dicarboxylic acid to the dermal layer, said ester moiety comprises a keratolytically active alcohol.

41. A method of increasing penetration of a salicylic acid derivative across dermal layer, comprising:

applying a mono or disalicylate ester derivative of an α,ω-dicarboxylic acid to the dermal layer.

42. Compounds of claims 1 to 11, which are functional to release a plurality of dermatologically-active compounds when delivered to a target site of the skin.

43. Compositions of claims 12 to 24, which are functional to release a plurality of dermatologically-active compounds when delivered to a target site of the skin.

44. The compounds of any of claims 1 to 11, for use in treating dermatological disorders.

45. Use of a compound comprising a mono- or diester of an α,ω-dicarboxylic acid, wherein the ester moiety of the dicarboxylic acid comprises a keratolytically active alcohol, for the manufacture of a pharmaceutical composition in topically, orally or parenterally administrable form, for treating dermatological disorders, said compound having the formula,



where *n* is in the range of 4 to 12; *m* is in the range of 0 to 8; R' is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl, OH, NHR", CONHR" and COOR"; R" is selected from the group consisting of alkyl, aryl, alkenyl, and benzyl; and Y is selected from the group consisting of H, alkyl, aryl, alkenyl, benzyl and X.

46. The use of claim 45, wherein the dermatological disorder is linked to hyperkeratinization, hypertrophy of the stratum corneum, excess sebum secretion, microbial infection, dermatophytoses, or increased conversion of testosterone to dihydrotestosterone.

47. The use of claim 45, wherein the dermatological disorder is selected from acne, seborrhoeic dermatitis, dandruff, psoriasis, ichthyosis, Rosacea, hirsutism, hypertrichosis and androgenic alopecia.

48. Use of a mono- or diester derivative of an α,ω-dicarboxylic acid wherein the ester moiety comprises a keratolytically active alcohol, for the manufacture of a composition for increasing penetration of the α,ω-dicarboxylic acid across a dermal layer.

49. The use according to any of claims 45 to 48, wherein the compound or derivative is a compound according to any of claims 1 to 11.